GlassScriptPhysician profile
Kelley M Lang
NPI 1851593024
$361.72
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Obesity Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $40.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $73.22 | 2019 | |
| Amarin Pharma, INC. | $47.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.53 | 2019-2020 | |
| Abbott Laboratories | $36.96 | 2019 | |
| Merck Sharp & Dohme LLC | $35.72 | 2019 | |
| Tandem Diabetes Care, INC. | $32.61 | 2019 | |
| Novo Nordisk INC | $27.50 | 2019-2020 | |
| Radius Health, INC. | $19.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.41 | 2019 | |
| Shire North American Group INC | $13.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.